Small Molecules for Targeted Anti-Cancer Therapy

At NTRC, we bridge the innovation gap by translating academic science into novel medicines. We perform the early phases of small molecule drug discovery in close collaboration with our academic partners.

Our team consists of industry experts in cell-based assays, protein crystallography and medicinal chemistry. We work on druggable protein target classes within the therapeutic areas oncology, autoimmune disease and neurodegenerative diseases. We have a strong focus on protein kinases.

Guido Zaman
Rogier Buijsman
Startup activities

Venture Challenge Fall 2010